Refractory Myelodysplastic/Myeloproliferative Neoplasm
4 clinical trials · Condition
◉ Watch Refractory Myelodysplastic/Myeloproliferative Neoplasm
| Record | Firm | Date |
|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCT04140487) | M.D. Anderson Cancer Center | 2019-12-17 |
Track Refractory Myelodysplastic/Myeloproliferative Neoplasm automatically
Every clearance here is in the API, with alerts when new ones post.